On chronic treatment (i.e., two weeks or more) with any medication severely affecting oral status (e.g. participants with gingival hypertrophy caused by anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive) or bone metabolism (e.g. anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants).
Affected by systemic diseases recognized to severely affect bone metabolism (e.g. Cushing's syndrome, Addison's disease, diabetes mellitus type 1, leukaemia, pernicious anaemia, malabsorption syndromes, chronic liver disease, rheumatoid arthritis).
Knowingly affected by HIV or Hepatitis.
History of local radiation therapy in the last five years.
Affected by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed.
Presenting an acute endodontic/periodontal lesion in the neighboring areas to the implant site.
Completely edentulous
With evident severe atrophy of the alveolar ridge that could preclude an implant placement (e.g. sharp knife edge ridge)
Severe bruxism or clenching habits
Smokers of > 5 cigarettes a day.
A daily alcohol intake >2 units/day.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality which may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.
Patients unable or not willing to return for follow-ups.

NCT02884401_exc_T1
Procedure
treatment
NCT02884401_exc_T2
Temporal
two weeks or more
NCT02884401_exc_T4
Condition
Cushing's syndrome
NCT02884401_exc_T5
Condition
Addison's disease
NCT02884401_exc_T6
Condition
diabetes mellitus type 1
NCT02884401_exc_T7
Condition
leukaemia
NCT02884401_exc_T8
Condition
pernicious anaemia
NCT02884401_exc_T9
Condition
malabsorption syndromes
NCT02884401_exc_T10
Condition
chronic liver disease
NCT02884401_exc_T11
Condition
rheumatoid arthritis
NCT02884401_exc_T3
Drug
immunosuppressive
NCT02884401_exc_T12
Drug
cyclosporine
NCT02884401_exc_T13
Drug
calcium antagonists
NCT02884401_exc_T14
Drug
anti-epileptics
NCT02884401_exc_T15
Condition
gingival hypertrophy
NCT02884401_exc_T16
Scope
anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive
NCT02884401_exc_T17
Observation
bone metabolism
NCT02884401_exc_T18
Drug
anticoagulant
NCT02884401_exc_T19
Drug
steroid
NCT02884401_exc_T20
Multiplier
equal or more 2.5mg a day
NCT02884401_exc_T21
Drug
prednisolone
NCT02884401_exc_T22
Temporal
>3 months
NCT02884401_exc_T23
Drug
anticonvulsants
NCT02884401_exc_T24
Drug
immunosuppressants
NCT02884401_exc_T25
Scope
anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants)
NCT02884401_exc_T26
Condition
Hepatitis
NCT02884401_exc_T27
Condition
HIV
NCT02884401_exc_T28
Procedure
local radiation therapy
NCT02884401_exc_T29
Temporal
last five years
NCT02884401_exc_T31
Condition
periodontal lesion
NCT02884401_exc_T32
Condition
n in t ontic/peri
NCT02884401_exc_T33
Condition
edentulous
NCT02884401_exc_T34
Qualifier
Completely
NCT02884401_exc_T36
Observation
clenching habits
NCT02884401_exc_T37
Observation
bruxism
NCT02884401_exc_T38
Person
Smokers
NCT02884401_exc_T39
Observation
cigarettes
NCT02884401_exc_T40
Multiplier
ett daily
NCT02884401_exc_T41
Observation
alcohol
NCT02884401_exc_T42
Multiplier
>2 units/day